PG 01037 dihydrochloride

Pricing Availability   Qty
说明: Selective D3 antagonist
化学名: N-[(2E)-4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]-2-buten-1-yl]-4-(2-pyridyl)-benzamide dihydrochloride
纯度: ≥98%
说明书
引用文献
评论
文献 (3)

生物活性 for PG 01037 dihydrochloride

PG 01037 dihydrochloride is a dopamine D3 receptor antagonist; 133-fold selective for D3 over D2 receptors in vitro (Ki values are 0.70, 93.3 and 375 nM for D3, D2 and D4 receptors respectively). Attenuates abnormal involuntary movements associated with L-DOPA (Cat. No. 3788) in rat models of Parkinson's disease. Inhibits the effects of methamphetamine; attenuates drug-induced behaviors in vivo.

化合物库 for PG 01037 dihydrochloride

PG 01037 dihydrochloride is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for PG 01037 dihydrochloride

分子量 554.34
公式 C26H26Cl2N4O.2HCl
储存 Desiccate at +4°C
纯度 ≥98%
CAS Number 675599-62-9
PubChem ID 90488894
InChI Key DACFFMAXBWGOKQ-CZEFNJPISA-N
Smiles ClC(C(Cl)=CC=C4)=C4N(CC3)CCN3C/C=C/CNC(C1=CC=C(C2=NC=CC=C2)C=C1)=O.Cl.Cl

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for PG 01037 dihydrochloride

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
water 11.09 20 温和加热
DMSO 55.43 100

制备储备液 for PG 01037 dihydrochloride

以下数据基于产品分子量 554.34。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 1.8 mL 9.02 mL 18.04 mL
5 mM 0.36 mL 1.8 mL 3.61 mL
10 mM 0.18 mL 0.9 mL 1.8 mL
50 mM 0.04 mL 0.18 mL 0.36 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for PG 01037 dihydrochloride

分析证书/产品说明书
选择另一批次:

按标靶查看相关产品

按产品操作查看相关产品

查看全部 D3 Receptor Antagonists

关键词: PG 01037 dihydrochloride, PG 01037 dihydrochloride supplier, PG01037, dopamine, receptors, D3, antagonists, dopaminergic, parkinsons, antiparkinsonian, parkinson's, Receptors, 3887, Tocris Bioscience

篇 PG 01037 dihydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 PG 01037 dihydrochloride 的引用文献。 您是否知道使用了 Tocris PG 01037 dihydrochloride 的优秀论文? 请告知我们.

PG 01037 dihydrochloride 的评论

目前没有该产品的评论。 Be the first to review PG 01037 dihydrochloride and earn rewards!

Have you used PG 01037 dihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.